Eugit Therapeutics
YC S22San Francisco, US · Founded 2022 · 2 employees · 1 known investors
Find your way into Eugit Therapeutics
Sign up to see every warm intro you have to Eugit Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eugit Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.
Also known as Eugit · Eugit Therapeutics Inc · EUGIT Tx · EUGIT Tx, EUGIT Therapeutics, Eugit, Eugit Therapeutics Inc
BiotechHealthtechMedical DevicesCell TherapySynthetic BiologyTherapeuticsOncologyBiotechnologyUnited States of AmericaAmerica / Canada
Founders & leadership· Y Combinator alumni (S22)
Eugit Therapeutics was founded in 2022 by Nizar Batada, Yoshi Fukazawa, and George Church.
NB

YF

GC

George ChurchScientific Advisor / Co-FounderProfessor at Harvard and MIT with a PhD in molecular biology, Church developed foundational methods for direct genome sequencing and molecular multiplexing that contributed to next-generation sequencing technologies. He has founded multiple biotech companies spanning genomics, gene editing, and therapeutics, and directs PersonalGenomes.org, an open-access genomic data resource.
Investors · 1
Related companies · 4
Modulari-TModulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.
WhiteLab GenomicsWhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.
LEAH LabsLEAH Labs develops CAR-T cell therapy for pets, starting with dogs with B cell lymphoma, using a virus-free gene editing platform to produce engineered cell therapy doses at low cost. It targets general practice veterinarians across the USA, with a longer-term goal of extending its therapies to humans.
Indee LabsIndee Labs develops a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to deliver nucleic acids, proteins, and gene editing complexes into patient and donor T cells. The technology targets T cell immunotherapy discovery, development, and manufacturing.
Companies working in the same space as Eugit Therapeutics.
Legal entities · 1
corporate structureEugit Therapeutics, Inc.
In the news
Frequently asked questions
- What does Eugit Therapeutics do?
- Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.
- Who founded Eugit Therapeutics?
- Eugit Therapeutics was founded by Nizar Batada, Yoshi Fukazawa, George Church in 2022.
- Who are Eugit Therapeutics's investors?
- Eugit Therapeutics's investors include Y Combinator.
- Where is Eugit Therapeutics headquartered?
- Eugit Therapeutics is headquartered in San Francisco, US.





